IS4706A - pharmaceutical compositions - Google Patents

pharmaceutical compositions

Info

Publication number: IS4706A
Authority: IS; Iceland
Prior art keywords: pharmaceutical compositions; pharmaceutical; compositions
Prior art date: 1995-11-21

Application number

IS4706A

Other languages

Icelandic (is)

Inventor

James Macrae Ross

Sarah Smith Janet

Original Assignee

Pfizer Research And Development Company, N.V/S.A.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-21

Filing date

1998-03-31

Publication date

1998-03-31

1998-03-31 Application filed by Pfizer Research And Development Company, N.V/S.A. filed Critical Pfizer Research And Development Company, N.V/S.A.

1998-03-31 Publication of IS4706A publication Critical patent/IS4706A/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IS4706A 1995-11-21 1998-03-31 pharmaceutical compositions IS4706A (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB9523752.5A GB9523752D0 (en)	1995-11-21	1995-11-21	Pharmaceutical formulations
PCT/EP1996/005020 WO1997018814A1 (en)	1995-11-21	1996-11-11	Pharmaceutical formulations

Publications (1)

Publication Number	Publication Date
IS4706A true IS4706A (en)	1998-03-31

Family

ID=10784188

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS4706A IS4706A (en)	1995-11-21	1998-03-31	pharmaceutical compositions

Country Status (29)

Country	Link
EP (1)	EP0862437A1 (en)
JP (1)	JPH10513481A (en)
KR (1)	KR19990071505A (en)
CN (1)	CN1215993A (en)
AP (1)	AP718A (en)
AR (1)	AR004335A1 (en)
AU (1)	AU709560B2 (en)
BG (1)	BG102438A (en)
BR (1)	BR9611626A (en)
CA (1)	CA2232715A1 (en)
CO (1)	CO4480020A1 (en)
CZ (1)	CZ155498A3 (en)
GB (1)	GB9523752D0 (en)
HR (1)	HRP960554A2 (en)
HU (1)	HUP9903734A3 (en)
IS (1)	IS4706A (en)
MA (1)	MA26410A1 (en)
MX (1)	MX9804008A (en)
NO (1)	NO982302L (en)
NZ (1)	NZ322053A (en)
OA (1)	OA10687A (en)
PE (1)	PE22898A1 (en)
PL (1)	PL326981A1 (en)
SK (1)	SK63098A3 (en)
TN (1)	TNSN96141A1 (en)
TR (1)	TR199800902T2 (en)
WO (1)	WO1997018814A1 (en)
YU (1)	YU62096A (en)
ZA (1)	ZA969722B (en)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5945125A (en) *	1995-02-28	1999-08-31	Temple University	Controlled release tablet
PL341575A1 (en) *	1997-12-16	2001-04-23	Pfizer Prod Inc	Composition effective in treating impotency
NZ506202A (en)	1998-03-19	2003-10-31	Bristol Myers Squibb Co	Biphasic controlled release delivery system for high solubility pharmaceuticals and method
GT199900061A (en) *	1998-05-15	2000-10-14	Pfizer	PHARMACEUTICAL FORMULATIONS.
EP0974343B1 (en) *	1998-07-22	2004-09-29	Pharma Pass II LLC	Process for manufacturing a solid metoprolol composition
EP0987020A1 (en) *	1998-09-04	2000-03-22	Pharma Pass LLC	Metoprolol composition and processes for manufacturing the same
CO5140079A1 (en) *	1998-10-14	2002-03-22	Novartis Ag	PHARMACEUTICAL COMPOSITION OF SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT FROM SUSTAINED LIBERATION AND METHOD TO RELEASE A PHARMACEUTICALLY ACTIVE AGENT
UA67802C2 (en)	1998-10-23	2004-07-15	Пфайзер Рісьоч Енд Дівелепмент Компані, Н.В./С.А.	CONTROLLED-RELEASE FORMULATIONS FOR ORAL ADMINISTRATION CONTAINING cGMP PDE-5 INHIBITOR (VARIANTS), METHOD FOR ITS PREPARATION AND METHOD FOR TREATING ERECTILE DYSFUNCTION
US20030059467A1 (en) *	2001-09-14	2003-03-27	Pawan Seth	Pharmaceutical composition comprising doxasozin
TWI312285B (en)	2001-10-25	2009-07-21	Depomed Inc	Methods of treatment using a gastric retained gabapentin dosage
US6723340B2 (en) *	2001-10-25	2004-04-20	Depomed, Inc.	Optimal polymer mixtures for gastric retentive tablets
US7612112B2 (en)	2001-10-25	2009-11-03	Depomed, Inc.	Methods of treatment using a gastric retained gabapentin dosage
US8329217B2 (en)	2001-11-06	2012-12-11	Osmotica Kereskedelmi Es Szolgaltato Kft	Dual controlled release dosage form
US7407955B2 (en)	2002-08-21	2008-08-05	Boehringer Ingelheim Pharma Gmbh & Co., Kg	8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
WO2005037247A2 (en) *	2003-10-17	2005-04-28	Ranbaxy Laboratories Limited	Oral matrix formulations of doxazosin
US20050255157A1 (en) *	2004-05-11	2005-11-17	Glenmark Pharmaceuticals Limited	Sustained release, mucoadhesive vaginal pharmaceutical compositions
KR100574554B1 (en) *	2004-05-28	2006-04-27	한미약품 주식회사	Sustained release composition for oral administration of niacin
DE102004054054A1 (en)	2004-11-05	2006-05-11	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Process for preparing chiral 8- (3-amino-piperidin-1-yl) -xanthines
KR100679111B1 (en) *	2004-11-20	2007-02-07	대우약품공업주식회사	Sustained-release tablets containing doxazosin
AU2006284053B2 (en) *	2005-08-22	2010-04-22	Novartis Ag	Pharmaceutical compositions comprising a pH-dependent drug, a pH modifier and a retarding agent
US20090176882A1 (en)	2008-12-09	2009-07-09	Depomed, Inc.	Gastric retentive gabapentin dosage forms and methods for using same
WO2007127630A1 (en)	2006-04-26	2007-11-08	Supernus Pharmaceuticals, Inc	Controlled released preparations of oxcarbazepine having sigmoidal release profile
EP1852108A1 (en)	2006-05-04	2007-11-07	Boehringer Ingelheim Pharma GmbH & Co.KG	DPP IV inhibitor formulations
PE20110235A1 (en)	2006-05-04	2011-04-14	Boehringer Ingelheim Int	PHARMACEUTICAL COMBINATIONS INCLUDING LINAGLIPTIN AND METMORPHINE
EP2016079A1 (en)	2006-05-04	2009-01-21	Boehringer Ingelheim International GmbH	Polymorphs
CN100396282C (en) *	2006-07-25	2008-06-25	山东省医药工业研究所	Slow released doxazosin mesilate capsule and its prepn process
SA07280459B1 (en)	2006-08-25	2011-07-20	بيورديو فارما إل. بي.	Tamper Resistant Oral Pharmaceutical Dosage Forms Comprising an Opioid Analgesic
US8377453B2 (en)	2008-03-11	2013-02-19	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
US8372432B2 (en)	2008-03-11	2013-02-12	Depomed, Inc.	Gastric retentive extended-release dosage forms comprising combinations of a non-opioid analgesic and an opioid analgesic
PE20091730A1 (en)	2008-04-03	2009-12-10	Boehringer Ingelheim Int	FORMULATIONS INVOLVING A DPP4 INHIBITOR
BRPI0916997A2 (en)	2008-08-06	2020-12-15	Boehringer Ingelheim International Gmbh	DPP-4 INHIBITOR AND ITS USE
TWI478712B (en)	2008-09-30	2015-04-01	Astellas Pharma Inc	Pharmaceutical composition for modified release
US20200155558A1 (en)	2018-11-20	2020-05-21	Boehringer Ingelheim International Gmbh	Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
KR101004205B1 (en)	2008-12-17	2010-12-24	동아제약주식회사	Controlled Release Compositions for Preparing Udenafil-Containing Sustained-Release Formulations
MA33046B1 (en)	2009-02-13	2012-02-01	Boehringer Ingelheim Int	Pharmaceutical composition containing sglt-2 inhibitor and dpp-iv inhibitor and optionally another agent against diabetes and its use
JP2012524125A (en)	2009-04-20	2012-10-11	エルセリクスセラピューティクスインコーポレイテッド	Chemosensory receptor ligand based therapy
US8828953B2 (en)	2009-04-20	2014-09-09	NaZura BioHealth, Inc.	Chemosensory receptor ligand-based therapies
US9901551B2 (en)	2009-04-20	2018-02-27	Ambra Bioscience Llc	Chemosensory receptor ligand-based therapies
JP2013512229A (en)	2009-11-27	2013-04-11	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Treatment of diabetic patients whose genotype has been identified with DDP-IV inhibitors such as linagliptin
US9198861B2 (en)	2009-12-22	2015-12-01	Mallinckrodt Llc	Methods of producing stabilized solid dosage pharmaceutical compositions containing morphinans
US20110150989A1 (en) *	2009-12-22	2011-06-23	Mallinkckrodt Inc.	Methods of Producing Stabilized Solid Dosage Pharmaceutical Compositions Containing Morphinans
AU2011249722B2 (en)	2010-05-05	2015-09-17	Boehringer Ingelheim International Gmbh	Combination therapy
CN107080846A (en)	2010-07-09	2017-08-22	詹姆斯.特林卡.格林	Combination immediate/delayed release delivery system for short half-life drugs including repagliflozin
WO2012054523A2 (en)	2010-10-19	2012-04-26	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
US9034883B2 (en)	2010-11-15	2015-05-19	Boehringer Ingelheim International Gmbh	Vasoprotective and cardioprotective antidiabetic therapy
CN103597071A (en)	2011-01-07	2014-02-19	埃尔舍利克斯治疗公司	Chemosensory receptor ligand-based therapies
CN102058555A (en) *	2011-01-13	2011-05-18	北京汇诚瑞祥医药技术有限公司	Doxazosin controlled release tablet
UY33937A (en)	2011-03-07	2012-09-28	Boehringer Ingelheim Int	PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
CN102188431A (en) *	2011-05-09	2011-09-21	浙江九旭药业有限公司	Doxazosin mesylate sustained-release tablets and preparation method thereof
US8741885B1 (en)	2011-05-17	2014-06-03	Mallinckrodt Llc	Gastric retentive extended release pharmaceutical compositions
US8658631B1 (en)	2011-05-17	2014-02-25	Mallinckrodt Llc	Combination composition comprising oxycodone and acetaminophen for rapid onset and extended duration of analgesia
US8858963B1 (en)	2011-05-17	2014-10-14	Mallinckrodt Llc	Tamper resistant composition comprising hydrocodone and acetaminophen for rapid onset and extended duration of analgesia
US20130143867A1 (en)	2011-12-02	2013-06-06	Sychroneuron Inc.	Acamprosate formulations, methods of using the same, and combinations comprising the same
US9555001B2 (en)	2012-03-07	2017-01-31	Boehringer Ingelheim International Gmbh	Pharmaceutical composition and uses thereof
WO2013158928A2 (en)	2012-04-18	2013-10-24	Elcelyx Therapeutics, Inc.	Chemosensory receptor ligand-based therapies
EP2849755A1 (en)	2012-05-14	2015-03-25	Boehringer Ingelheim International GmbH	A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
WO2013171166A1 (en)	2012-05-14	2013-11-21	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp-4 inhibitor for use in the treatment of sirs and/or sepsis
WO2013174767A1 (en)	2012-05-24	2013-11-28	Boehringer Ingelheim International Gmbh	A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
JP2016520653A (en)	2013-06-05	2016-07-14	シンクロニューロンインコーポレイテッド	Acamprosate formulation, method of using the same, and combination containing the same
JP6615109B2 (en)	2014-02-28	2019-12-04	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Medical use of DPP-4 inhibitors
CN105616378A (en) *	2014-10-31	2016-06-01	康普药业股份有限公司	Fluconazole capsule and preparation method therefor
US10155000B2 (en)	2016-06-10	2018-12-18	Boehringer Ingelheim International Gmbh	Medical use of pharmaceutical combination or composition
US12097189B1 (en)	2024-02-09	2024-09-24	Astellas Pharma Inc.	Pharmaceutical composition for modified release

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IT1198386B (en) *	1982-07-06	1988-12-21	Lepetit Spa	A PROTRACTED RELEASE PRODUCT CONTAINING SULOCTIDYL
US4765989A (en) *	1983-05-11	1988-08-23	Alza Corporation	Osmotic device for administering certain drugs
US4837111A (en) *	1988-03-21	1989-06-06	Alza Corporation	Dosage form for dispensing drug for human therapy
IL92966A (en) *	1989-01-12	1995-07-31	Pfizer	Dispensing devices powered by hydrogel
PT98374A (en) *	1990-07-23	1994-01-31	Alza Corp	OSMOTIC DEVICE FOR NICOTINE SYSTEMIC ADMINISTRATION AND NICOTINE BASED PROCESS

1995
- 1995-11-21 GB GBGB9523752.5A patent/GB9523752D0/en active Pending
1996
- 1996-11-11 HU HU9903734A patent/HUP9903734A3/en unknown
- 1996-11-11 NZ NZ322053A patent/NZ322053A/en unknown
- 1996-11-11 WO PCT/EP1996/005020 patent/WO1997018814A1/en not_active Application Discontinuation
- 1996-11-11 SK SK630-98A patent/SK63098A3/en unknown
- 1996-11-11 TR TR1998/00902T patent/TR199800902T2/en unknown
- 1996-11-11 CN CN96198486A patent/CN1215993A/en active Pending
- 1996-11-11 AU AU75721/96A patent/AU709560B2/en not_active Ceased
- 1996-11-11 JP JP9519364A patent/JPH10513481A/en active Pending
- 1996-11-11 CA CA002232715A patent/CA2232715A1/en not_active Abandoned
- 1996-11-11 BR BR9611626A patent/BR9611626A/en not_active Application Discontinuation
- 1996-11-11 EP EP96938215A patent/EP0862437A1/en not_active Withdrawn
- 1996-11-11 KR KR1019980703777A patent/KR19990071505A/en not_active Ceased
- 1996-11-11 CZ CZ981554A patent/CZ155498A3/en unknown
- 1996-11-11 PL PL96326981A patent/PL326981A1/en unknown
- 1996-11-20 MA MA24397A patent/MA26410A1/en unknown
- 1996-11-20 PE PE1996000831A patent/PE22898A1/en not_active Application Discontinuation
- 1996-11-20 ZA ZA9609722A patent/ZA969722B/en unknown
- 1996-11-20 AR ARP960105252A patent/AR004335A1/en unknown
- 1996-11-20 YU YU62096A patent/YU62096A/en unknown
- 1996-11-20 TN TNTNSN96141A patent/TNSN96141A1/en unknown
- 1996-11-21 HR HR9523752.5A patent/HRP960554A2/en not_active Application Discontinuation
- 1996-11-21 CO CO96061449A patent/CO4480020A1/en unknown
- 1996-11-21 AP APAP/P/1996/000883A patent/AP718A/en active
1998
- 1998-03-31 IS IS4706A patent/IS4706A/en unknown
- 1998-05-08 BG BG102438A patent/BG102438A/en unknown
- 1998-05-19 OA OA9800058A patent/OA10687A/en unknown
- 1998-05-20 MX MX9804008A patent/MX9804008A/en unknown
- 1998-05-20 NO NO982302A patent/NO982302L/en not_active Application Discontinuation

Also Published As

Publication number	Publication date
SK63098A3 (en)	1999-05-07
CN1215993A (en)	1999-05-05
HUP9903734A2 (en)	2000-03-28
OA10687A (en)	2002-11-27
NZ322053A (en)	1999-11-29
NO982302L (en)	1998-07-17
TR199800902T2 (en)	1998-09-21
MA26410A1 (en)	2004-12-20
AP718A (en)	1999-01-06
BG102438A (en)	1999-01-29
PE22898A1 (en)	1998-05-07
AP9600883A0 (en)	1997-01-31
HUP9903734A3 (en)	2000-04-28
PL326981A1 (en)	1998-11-09
TNSN96141A1 (en)	2005-03-15
CA2232715A1 (en)	1997-05-29
ZA969722B (en)	1998-05-20
NO982302D0 (en)	1998-05-20
EP0862437A1 (en)	1998-09-09
WO1997018814A1 (en)	1997-05-29
YU62096A (en)	1999-03-04
BR9611626A (en)	1999-06-01
GB9523752D0 (en)	1996-01-24
CO4480020A1 (en)	1997-07-09
AU709560B2 (en)	1999-09-02
AU7572196A (en)	1997-06-11
MX9804008A (en)	1998-09-30
CZ155498A3 (en)	1999-03-17
JPH10513481A (en)	1998-12-22
AR004335A1 (en)	1998-11-04
HRP960554A2 (en)	1998-02-28
KR19990071505A (en)	1999-09-27

Publication	Publication Date	Title
IS4706A (en)	1998-03-31	pharmaceutical compositions
NO962606D0 (en)	1996-06-19	Pharmaceutical composition
CY2005007I1 (en)	2009-11-04	PHARMACEUTICAL COMPOSITIONS CONTAINING DARIFENACINE
FI20071025L (en)	2007-12-28	Pharmaceutical compositions
FI974241A7 (en)	1997-11-14	BPM-15 compositions
ID18352A (en)	1998-04-02	PHARMACEUTICAL COMPOSITIONS
DE69617029D1 (en)	2001-12-20	ORGANOTON COMPOSITIONS
NO981568D0 (en)	1998-04-06	Randtennings-priming compositions
DE69614407D1 (en)	2001-09-13	PHARMACEUTICAL COMPOSITIONS
BR9507768A (en)	1997-09-02	Pharmaceutical composition
LV11727A (en)	1997-04-20	Pharmaceutical composition
FI973229A0 (en)	1997-08-05	New pharmaceutical composition
FI943705L (en)	1995-02-14	Pharmaceutical compositions
IS2515B (en)	2009-06-15	pharmaceutical compositions
PT941100E (en)	2003-10-31	PHARMACEUTICAL COMPOSITIONS
FI973280A0 (en)	1997-08-08	Pharmaceutical composition
ITMI942166A0 (en)	1994-10-21	PHARMACEUTICAL COMPOSITIONS MIORELAXANTS
DE69603228D1 (en)	1999-08-19	Aluminoxanate compositions
EE200000330A (en)	2001-08-15	Pharmaceutical compositions
FI940726A7 (en)	1994-08-19	Pharmaceutical compositions
ATE206150T1 (en)	2001-10-15	DYE-STABILIZED COMPOSITIONS
BR9605777A (en)	1998-08-25	Pharmaceutical composition
FI962738L (en)	1996-07-03	Pharmaceutical compositions
FI954050L (en)	1996-03-02	Pharmaceutical compositions
NO964309D0 (en)	1996-10-10	Pharmaceutical composition